サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405874

ヒアルロン酸の市場規模、シェア、動向分析レポート：用途別、地域別、セグメント予測、2024年～2030年

Hyaluronic Acid Market Size, Share & Trends Analysis Report By Application (Dermal Fillers, Osteoarthritis, Ophthalmic, Vesicoureteral Reflux), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
ヒアルロン酸の市場規模、シェア、動向分析レポート：用途別、地域別、セグメント予測、2024年～2030年
出版日: 2023年12月19日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヒアルロン酸市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のヒアルロン酸市場規模は2024年から2030年にかけて7.7%のCAGRを記録し、2030年には167億5,000万米ドルに達すると予測されています。

化学物質に対する人々の関心の高まり、迅速で明白な結果を得たいという願望、回復時間の短縮などの要因は、インパクトの強いレンダリング促進要因です。業界は、先進国や発展途上地域での美容施術の採用増加により急速に発展しています。ステントや人工血管のような心臓血管インプラントにおけるヒアルロン酸表面の使用は、アンチエイジング製品に対する意識の高まりと相まって、適合性を向上させるために増加しており、これが成長を後押ししています。

ヒアルロン酸ベースの皮膚充填剤の有効性と明らかな結果が、この人口基盤を引き付けています。さらに、COVID-19の大流行は多くの業界の力学を変え、移動制限、社会的距離、慣行の見直しが"新常識"となっています。化粧品業界が徐々に営業を再開するなか、多くの医師が美容整形手術の問い合わせが大幅に増えたと報告しています。さらに、鎖国によって各専門家がテレビ会議設備を利用するようになり、人々は自分の外見をより意識するようになった。場合によっては、人々は美容治療を選ぶようになり、これは"ズーム・ブーム"あるいは"ズーム効果"と呼ばれています。

世界中の美容外科医は、特に米国、オーストラリア、日本などの国々で、パンデミックの結果として患者数が大幅に増加していることを目の当たりにしています。北米は2022年に最大の売上シェアを占めました。高価格であっても短期治療レジメンが好まれること、変形性関節症などの対象疾患の流行が高いシェアの主な要因です。2022年、北米地域で最も有利な製品用途は、変形性関節症の管理用の皮膚充填剤とビスコス・サプリメントの形態でした。アジア太平洋地域は、予測期間中に最も速いCAGRを記録すると予想されています。

中国と日本では老年人口が増加しており、アンチエイジング製品およびサービスの大規模な顧客基盤となっています。製品の用途や効能に関する意識の高まりも需要を後押ししています。さらに、可処分所得水準の向上がこの地域の拡大をさらに後押ししています。欧州は過去2年間に目覚ましい変化を遂げました。需要の拡大により、新規参入企業による価格競争が激化しています。WHOは最近、英国とドイツにおける肥満の蔓延を発表しました。高齢化人口の増加と肥満の関係は、欧州地域セクターの潜在的な原動力です。

ヒアルロン酸市場レポート・ハイライト

  • 変形性関節症セグメントは世界産業を支配し、2023年には全体収益の最大シェアを占めました。
  • 肥満による変形性関節症や関節痛の増加が、治療としてのヒアルロン酸注射の需要を高めています。
  • ヒアルロン酸は衝撃吸収剤やクッションとして働き、関節を潤滑にするため、適切な機能を助ける。
  • ヒアルロン酸/ヒアルロン酸を有効成分とする眼科手術用製品は数多くあります。
  • これらにはVitrax、Healon、Amivisc Plus、Amvisc、Hylan G-F20、Opeganなどがあります。
  • 加齢に伴う眼疾患、ドライアイ症候群、成人視力障害、糖尿病などの慢性疾患の有病率の増加が、このセグメントの成長を導く主な要因です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ヒアルロン酸市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ヒアルロン酸市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 ヒアルロン酸市場：用途の推定・動向分析

  • 用途市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 用途別の世界のヒアルロン酸市場の見通し
  • 以下の市場規模、予測および動向分析、2018～2030年
    • 皮膚充填剤
    • 変形性関節症
    • 眼科
    • 膀胱尿管逆流症

第5章 ヒアルロン酸市場：地域の推定・動向分析

  • 地域市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 市場規模と予測動向分析、2018～2030年：
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • 主要ディストリビューターとチャネルパートナーのリスト
    • 主要顧客
    • 主要企業シェア分析、2023年
    • Allergan
    • Sanofi
    • Genzyme Corporation
    • Anika Therapeutics, Inc.
    • Salix Pharmaceuticals
    • Seikagaku Corporation
    • F. Hoffmann-La Roche Ag
    • Galderma Laboratories LP
    • Zimmer Biomet
    • Smith &Nephew Plc
    • Ferring BV
    • Lifecore Biomedical, LLC
    • HTL Biotechnology
    • Shiseido Company, Limited
    • Bloomage Biotechnology Corporation Limited
    • LG Life Sciences Ltd（LG Chem.）
    • Maruha Nichiro, Inc.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Hyaluronic Acid market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 4 U.S. Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 5 Canada Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 6 Europe Hyaluronic Acid market, by region, 2018 - 2030 (USD Million)
  • Table 7 Europe Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 8 Germany Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 9 UK Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 10 France Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 11 Italy Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 12 Spain Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 13 Denmark Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 14 Sweden Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 15 Norway Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific Hyaluronic Acid market, by region, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 18 China Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 19 Japan Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 20 India Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 21 South Korea Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 22 Australia Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 23 Thailand Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 24 Latin America Hyaluronic Acid market, by region, 2018 - 2030 (USD Million)
  • Table 25 Latin America Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 26 Brazil Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 27 Mexico Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 28 Argentina Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 29 MEA Hyaluronic Acid market, by region, 2018 - 2030 (USD Million)
  • Table 30 MEA Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 31 South Africa Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 33 UAE Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)
  • Table 34 Kuwait Hyaluronic Acid market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Hyaluronic Acid market: market outlook
  • Fig. 14 Hyaluronic Acid competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Hyaluronic Acid market driver impact
  • Fig. 20 Hyaluronic Acid market restraint impact
  • Fig. 21 Hyaluronic Acid market strategic initiatives analysis
  • Fig. 22 Hyaluronic Acid market: Application movement analysis
  • Fig. 23 Hyaluronic Acid market: Application outlook and key takeaways
  • Fig. 24 Dermal fillers market estimates and forecast, 2018 - 2030
  • Fig. 25 Osteoarthritis market estimates and forecast, 2018 - 2030
  • Fig. 26 Single-injection market estimates and forecast, 2018 - 2030
  • Fig. 27 Three-injection market estimates and forecast, 2018 - 2030
  • Fig. 28 Five-injection market estimates and forecast, 2018 - 2030
  • Fig. 29 Ophthalmic market estimates and forecast, 2018 - 2030
  • Fig. 30 Vesicoureteral reflux market estimates and forecast, 2018 - 2030
  • Fig. 31 Global Hyaluronic Acid market: Regional movement analysis
  • Fig. 32 Global Hyaluronic Acid market: Regional outlook and key takeaways
  • Fig. 33 Global Hyaluronic Acid market share and leading players
  • Fig. 34 North America market share and leading players
  • Fig. 35 Europe market share and leading players
  • Fig. 36 Asia Pacific market share and leading players
  • Fig. 37 Latin America market share and leading players
  • Fig. 38 Middle East & Africa market share and leading players
  • Fig. 39 North America: SWOT
  • Fig. 40 Europe SWOT
  • Fig. 41 Asia Pacific SWOT
  • Fig. 42 Latin America SWOT
  • Fig. 43 MEA SWOT
  • Fig. 44 North America, by country
  • Fig. 45 North America
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030
  • Fig. 47 U.S.
  • Fig. 48 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 49 Canada
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecasts, 2018 - 2030
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 57 France
  • Fig. 58 France market estimates and forecasts, 2018 - 2030
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 65 Sweden
  • Fig. 66 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 67 Norway
  • Fig. 68 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 71 China
  • Fig. 72 China market estimates and forecasts, 2018 - 2030
  • Fig. 73 Japan
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 75 India
  • Fig. 76 India market estimates and forecasts, 2018 - 2030
  • Fig. 77 Thailand
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 79 South Korea
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 81 Australia
  • Fig. 82 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 85 Brazil
  • Fig. 86 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 87 Mexico
  • Fig. 88 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 101 Market share of key market players- Hyaluronic Acid market
目次
Product Code: 978-1-68038-333-1

Hyaluronic Acid Market Growth & Trends:

The global hyaluronic acid market size is expected to reach USD 16.75 billion by 2030, registering a CAGR of 7.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors, such as increasing concern of population regarding chemicals, desire to get quick and evident results, and shorter recovery time are high impact rendering drivers. The industry is evolving rapidly due to the increasing adoption of aesthetic procedures in developed and developing regions. Increasing the use of hyaluronic acid surfaces in cardiovascular implants, such as stents and vascular grafts, for improving compatibility coupled with the growing awareness about anti-aging products is fueling the growth.

The efficacy and evident results of hyaluronic acid-based dermal fillers are attracting this population base. Furthermore, the COVID-19 pandemic has changed the dynamics of many industries, with movement restrictions, social distancing, and revised practices becoming the "new normal." As the cosmetic industry is gradually resuming its operations, a number of doctors have reported a significant increase in inquiries for aesthetic surgeries. Moreover, the lockdown has encouraged all professionals to use video-conferencing facilities, which has made people more conscious of their looks. In some cases, it has led people to opt for cosmetic treatments; this is termed the "Zoom Boom" or the "Zoom effect."

Cosmetic surgeons across the world have witnessed a significant increase in the number of patients as a result of the pandemic, particularly in countries, such as the U.S., Australia, and Japan. North America held the maximum revenue share in 2022. Preference for short-treatment regimens, even though high-priced, and the prevalence of target diseases, such as osteoarthritis, are the key factors attributed to the high share. In 2022, the most lucrative product applications in the North America region were in the form of dermal fillers and viscos supplements for the management of osteoarthritis. Asia Pacific is anticipated to register the fastest CAGR during the forecast period.

The growing geriatric population in China and Japan provide a large customer base for anti-aging products and services. Rising awareness about product applications and efficacy also fuels the demand. In addition, increasing disposable income levels are further supporting the region's expansion. Europe has undergone impressive changes over the last 2 years. The growing demand is witnessing increasing price competition owing to new entrants. The WHO recently announced the obesity epidemic in the U.K. and Germany. The relationship between the increasing aging population and obesity is a potential driver for the Europe regional sector

Hyaluronic Acid Market Report Highlights:

  • The osteoarthritis segment dominated the global industry and accounted for the maximum share of the overall revenue in 2023
  • The rising obesity resulting in osteoarthritis and joint pain has increased the demand for hyaluronic acid injections as a treatment
  • Hyaluronic acid acts as a shock absorber or a cushion and lubricates the joints, thus helping in proper functioning
  • There are a number of ophthalmic surgical products that use hyaluronan/hyaluronic acid as an active ingredient
  • These include Vitrax, Healon, Amivisc Plus, Amvisc, Hylan G-F20, and Opegan
  • The increasing prevalence of age-related eye diseases, dry eye syndrome, adult-vision impairments, and chronic diseases, such as diabetes, are major factors leading to segment growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hyaluronic Acid Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Geriatric Population
      • 3.2.1.2. Growing Awareness for Antiaging Products
      • 3.2.1.3. High Prevalence of Target Diseases
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Associated adverse effects of hyaluronic acid
      • 3.2.2.2. High cost of products and related services
  • 3.3. Hyaluronic Acid Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Hyaluronic Acid Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Hyaluronic Acid Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 - 2030 for the following
    • 4.4.1. Dermal fillers
      • 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Osteoarthritis
      • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.2. Single-injection
      • 4.4.2.2.1 Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.3. Three-injection
      • 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.2.3. Five-injection
      • 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Ophthalmic
      • 4.4.3.3. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4. Vesicoureteral reflux
      • 4.4.2.3. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Hyaluronic Acid Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. Market Size, & Forecasts Trend Analysis, 2018 - 2030:
  • 5.5. North America
    • 5.5.1. U.S.
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.2. Canada
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Europe
    • 5.6.1. UK
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.2. Germany
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.3. France
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.4. Italy
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework/ reimbursement structure
      • 5.6.4.3. Competitive scenario
      • 5.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.5. Spain
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework/ reimbursement structure
      • 5.6.5.3. Competitive scenario
      • 5.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.6. Norway
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework/ reimbursement structure
      • 5.6.6.3. Competitive scenario
      • 5.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.7. Sweden
      • 5.6.7.1. Key country dynamics
      • 5.6.7.2. Regulatory framework/ reimbursement structure
      • 5.6.7.3. Competitive scenario
      • 5.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.6.8. Denmark
      • 5.6.8.1. Key country dynamics
      • 5.6.8.2. Regulatory framework/ reimbursement structure
      • 5.6.8.3. Competitive scenario
      • 5.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Asia Pacific
    • 5.7.1. Japan
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.2. China
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.3. India
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.4. Australia
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.5. South Korea
      • 5.7.5.1. Key country dynamics
      • 5.7.5.2. Regulatory framework/ reimbursement structure
      • 5.7.5.3. Competitive scenario
      • 5.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.7.6. Thailand
      • 5.7.6.1. Key country dynamics
      • 5.7.6.2. Regulatory framework/ reimbursement structure
      • 5.7.6.3. Competitive scenario
      • 5.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.8. Latin America
    • 5.8.1. Brazil
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Regulatory framework/ reimbursement structure
      • 5.8.1.3. Competitive scenario
      • 5.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.8.2. Mexico
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework/ reimbursement structure
      • 5.8.2.3. Competitive scenario
      • 5.8.2.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.8.3. Argentina
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework/ reimbursement structure
      • 5.8.3.3. Competitive scenario
      • 5.8.3.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.9. MEA
    • 5.9.1. South Africa
      • 5.9.1.1. Key country dynamics
      • 5.9.1.2. Regulatory framework/ reimbursement structure
      • 5.9.1.3. Competitive scenario
      • 5.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.9.2. Saudi Arabia
      • 5.9.2.1. Key country dynamics
      • 5.9.2.2. Regulatory framework/ reimbursement structure
      • 5.9.2.3. Competitive scenario
      • 5.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.9.3. UAE
      • 5.9.3.1. Key country dynamics
      • 5.9.3.2. Regulatory framework/ reimbursement structure
      • 5.9.3.3. Competitive scenario
      • 5.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.9.4. Kuwait
      • 5.9.4.1. Key country dynamics
      • 5.9.4.2. Regulatory framework/ reimbursement structure
      • 5.9.4.3. Competitive scenario
      • 5.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2023
    • 6.3.4. Allergan
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Sanofi
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. Genzyme Corporation
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Anika Therapeutics, Inc.
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Salix Pharmaceuticals
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Seikagaku Corporation
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. F. Hoffmann-La Roche Ag
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives
    • 6.3.11. Galderma Laboratories L.P.
      • 6.3.11.1. Company overview
      • 6.3.11.2. Financial performance
      • 6.3.11.3. Product benchmarking
      • 6.3.11.4. Strategic initiatives
    • 6.3.12. Zimmer Biomet
      • 6.3.12.1. Company overview
      • 6.3.12.2. Financial performance
      • 6.3.12.3. Product benchmarking
      • 6.3.12.4. Strategic initiatives
    • 6.3.13. Smith & Nephew Plc
      • 6.3.13.1. Company overview
      • 6.3.13.2. Financial performance
      • 6.3.13.3. Product benchmarking
      • 6.3.13.4. Strategic initiatives
    • 6.3.14. Ferring B.V.
      • 6.3.14.1. Company overview
      • 6.3.14.2. Financial performance
      • 6.3.14.3. Product benchmarking
      • 6.3.14.4. Strategic initiatives
    • 6.3.15. Lifecore Biomedical, LLC
      • 6.3.15.1. Company overview
      • 6.3.15.2. Financial performance
      • 6.3.15.3. Product benchmarking
      • 6.3.15.4. Strategic initiatives
    • 6.3.16. HTL Biotechnology
      • 6.3.16.1. Company overview
      • 6.3.16.2. Financial performance
      • 6.3.16.3. Product benchmarking
      • 6.3.16.4. Strategic initiatives
    • 6.3.17. Shiseido Company, Limited
      • 6.3.17.1. Company overview
      • 6.3.17.2. Financial performance
      • 6.3.17.3. Product benchmarking
      • 6.3.17.4. Strategic initiatives
    • 6.3.18. Bloomage Biotechnology Corporation Limited
      • 6.3.18.1. Company overview
      • 6.3.18.2. Financial performance
      • 6.3.18.3. Product benchmarking
      • 6.3.18.4. Strategic initiatives
    • 6.3.19. LG Life Sciences Ltd (LG Chem.)
      • 6.3.19.1. Company overview
      • 6.3.19.2. Financial performance
      • 6.3.19.3. Product benchmarking
      • 6.3.19.4. Strategic initiatives
    • 6.3.20. Maruha Nichiro, Inc.
      • 6.3.20.1. Company overview
      • 6.3.20.2. Financial performance
      • 6.3.20.3. Product benchmarking
      • 6.3.20.4. Strategic initiatives